Related Experiment Video

Updated: May 27, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options

Megan V Caram1, Scott M Schuetze

  • 1Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Michigan, USA.

Journal of Surgical Oncology
|November 10, 2011
PubMed

Insights

Gastrointestinal stromal tumors (GIST) are treated with targeted therapies that inhibit C-KIT and PDGFR mutations. These small molecule inhibitors have significantly improved outcomes for advanced GIST patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gastrointestinal Medicine

Background:

  • Gastrointestinal stromal tumor (GIST) is the most common gastrointestinal sarcoma.
  • GIST typically involves mutations in c-kit or platelet-derived growth factor receptor (PDGFR) genes.
  • These genes encode tyrosine-kinase receptors C-KIT and PDGFR.

Purpose of the Study:

  • To review the impact of targeted therapies on advanced GIST.
  • To highlight the efficacy of small molecule inhibitors against mutant C-KIT and PDGFR.

Main Methods:

  • Review of recent clinical data and therapeutic developments.
  • Analysis of molecular mechanisms underlying GIST targeted therapy.

Main Results:

  • Small molecule inhibitors targeting mutant C-KIT and PDGFR show high activity in advanced GIST.
  • These targeted therapies have transformed treatment paradigms and patient prognosis.

Conclusions:

  • Targeted therapy represents a significant advancement in managing advanced GIST.
  • Inhibition of specific kinase mutations offers a highly effective treatment strategy for GIST.

More Related Videos

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...